BioMark Diagnostics Inc (BioMark Diagnostics) is an oncology-focused medical equipment company. It owns and develops multiple intellectual properties in the detection and quantitation of metabolites. The company’s product portfolio includes cancer diagnostic tools, amantadine, cancer management solutions, biomarkers and others. BioMark Diagnostics offers services such as multiple intellectual properties in the detection and quantitation of metabolites, science of metabolomics research and development, research and technology development, clinical trials,early state cancer detection and treatment technologies. The company’s products are used in the treatment of cancers including lung, breast, prostate and gastrointestinal (GI)cancers. BioMark Diagnostics is headquartered in Richmond, British Columbia, Canada.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company BioMark Diagnostics Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- BioMark Diagnostics Inc Company Overview
- BioMark Diagnostics Inc Company Snapshot
- BioMark Diagnostics Inc Pipeline Products and Ongoing Clinical Trials Overview
- BioMark Diagnostics Inc - Pipeline Analysis Overview
- BioMark Diagnostics Inc - Key Facts
- BioMark Diagnostics Inc - Major Products and Services
- BioMark Diagnostics Inc Pipeline Products by Development Stage
- BioMark Diagnostics Inc Ongoing Clinical Trials by Trial Status
- BioMark Diagnostics Inc Pipeline Products Overview
- Biomarker Assay - Ovarian Cancer
- Biomarker Assay - Ovarian Cancer Product Overview
- Detection Test - COVID-19
- Detection Test - COVID-19 Product Overview
- Injectable Drug Delivery Device
- Injectable Drug Delivery Device Product Overview
- Liquid Biopsy Metabolic Panel Assay - Breast Cancer
- Liquid Biopsy Metabolic Panel Assay - Breast Cancer Product Overview
- Liquid Biopsy Metabolic Panel Assay - Glioblastoma
- Liquid Biopsy Metabolic Panel Assay - Glioblastoma Product Overview
- Liquid Biopsy Metabolic Panel Assay - Head And Neck Cancer
- Liquid Biopsy Metabolic Panel Assay - Head And Neck Cancer Product Overview
- Liquid Biopsy Metabolic Panel Assay - Lung Cancer
- Liquid Biopsy Metabolic Panel Assay - Lung Cancer Product Overview
- Liquid Biopsy Metabolic Panel Assay - Lung Cancer Clinical Trial
- Metabolomics-based Diagnostic Assay - Breast Cancer
- Metabolomics-based Diagnostic Assay - Breast Cancer Product Overview
- Metabolomics-based Diagnostic Assay - Cervical Cancer
- Metabolomics-based Diagnostic Assay - Cervical Cancer Product Overview
- Metabolomics-based Diagnostic Assay - Colorectal Cancer
- Metabolomics-based Diagnostic Assay - Colorectal Cancer Product Overview
- Metabolomics-based Diagnostic Assay - Gastrointestinal Cancer
- Metabolomics-based Diagnostic Assay - Gastrointestinal Cancer Product Overview
- Metabolomics-Based Diagnostic Assay - Melanoma
- Metabolomics-Based Diagnostic Assay - Melanoma Product Overview
- Metabolomics-based Diagnostic Assay - Prostate Cancer
- Metabolomics-based Diagnostic Assay - Prostate Cancer Product Overview
- POC Device - Monoclonal Antibodies
- POC Device - Monoclonal Antibodies Product Overview
- SSAT-Amantadine Assay - ELISA KIT
- SSAT-Amantadine Assay - ELISA KIT Product Overview
- SSAT-Amantadine Assay - Raman SERS
- SSAT-Amantadine Assay - Raman SERS Product Overview
- SSAT1 - Acetylamantadine Assay
- SSAT1 - Acetylamantadine Assay Product Overview
- BioMark Diagnostics Inc - Key Competitors
- BioMark Diagnostics Inc - Key Employees
- BioMark Diagnostics Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- BioMark Diagnostics Inc, Recent Developments
- Dec 11, 2024: BioMark’s Liquid Biopsy Platform Takes A Major Step Forward in Breast Cancer Diagnosiswith AI-powered ER Status Prediction
- Dec 10, 2024: BioMark’s Liquid Biopsy Platform Takes A Major Step Forward in Breast Cancer Diagnosis with AI-powered ER Status Prediction
- Nov 05, 2024: BioMark Expands its Liquid Biopsy Platform with two Groundbreaking Publications in Breast Cancer Detection
- Sep 24, 2024: Biomark Diagnostics and Principal Investigators Publish an Important Approach Using Metabolomics and ML to Identify Biomarkers for Nen
- Sep 10, 2024: BioMark Diagnostics Completes Testing of Over 5,400 subjects as Part of a Validation Study for Early Lung Cancer Detection
- Aug 26, 2024: Biomark Diagnostics to Showcase Innovative Liquid Biopsy Technology at H.C. Wainwright's 26th Annual Global Investment conference in New York
- Apr 09, 2024: BioMark to Advance Development of Cancer Treatment for Glioblastoma
- Apr 09, 2024: Biomark to Advance Development of Cancer Treatment for Glioblastoma
- Dec 04, 2023: Biomark Announces Recent New Patent Granted in Canada to Support Its Liquid Biopsy Based Legacy Assay
- Oct 24, 2023: BioMark to Unveil Results of Its Early Breast Cancer Study at the Upcoming San Antonio Breast Cancer Symposium
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- BioMark Diagnostics Inc Pipeline Products and Ongoing Clinical Trials Overview
- BioMark Diagnostics Inc Pipeline Products by Equipment Type
- BioMark Diagnostics Inc Pipeline Products by Indication
- BioMark Diagnostics Inc Ongoing Clinical Trials by Trial Status
- BioMark Diagnostics Inc, Key Facts
- BioMark Diagnostics Inc, Major Products and Services
- BioMark Diagnostics Inc Number of Pipeline Products by Development Stage
- BioMark Diagnostics Inc Pipeline Products Summary by Development Stage
- BioMark Diagnostics Inc Ongoing Clinical Trials by Trial Status
- BioMark Diagnostics Inc Ongoing Clinical Trials Summary
- Biomarker Assay - Ovarian Cancer - Product Status
- Biomarker Assay - Ovarian Cancer - Product Description
- Detection Test - COVID-19 - Product Status
- Detection Test - COVID-19 - Product Description
- Injectable Drug Delivery Device - Product Status
- Injectable Drug Delivery Device - Product Description
- Liquid Biopsy Metabolic Panel Assay - Breast Cancer - Product Status
- Liquid Biopsy Metabolic Panel Assay - Breast Cancer - Product Description
- Liquid Biopsy Metabolic Panel Assay - Glioblastoma - Product Status
- Liquid Biopsy Metabolic Panel Assay - Glioblastoma - Product Description
- Liquid Biopsy Metabolic Panel Assay - Head And Neck Cancer - Product Status
- Liquid Biopsy Metabolic Panel Assay - Head And Neck Cancer - Product Description
- Liquid Biopsy Metabolic Panel Assay - Lung Cancer - Product Status
- Liquid Biopsy Metabolic Panel Assay - Lung Cancer - Product Description
- Liquid Biopsy Metabolic Panel Assay - Lung Cancer - Excretion of Acetylamantadine (AA) by Lung Cancer Patients During a Chemotherapy Regimen
- Metabolomics-based Diagnostic Assay - Breast Cancer - Product Status
- Metabolomics-based Diagnostic Assay - Breast Cancer - Product Description
- Metabolomics-based Diagnostic Assay - Cervical Cancer - Product Status
- Metabolomics-based Diagnostic Assay - Cervical Cancer - Product Description
- Metabolomics-based Diagnostic Assay - Colorectal Cancer - Product Status
- Metabolomics-based Diagnostic Assay - Colorectal Cancer - Product Description
- Metabolomics-based Diagnostic Assay - Gastrointestinal Cancer - Product Status
- Metabolomics-based Diagnostic Assay - Gastrointestinal Cancer - Product Description
- Metabolomics-Based Diagnostic Assay - Melanoma - Product Status
- Metabolomics-Based Diagnostic Assay - Melanoma - Product Description
- Metabolomics-based Diagnostic Assay - Prostate Cancer - Product Status
- Metabolomics-based Diagnostic Assay - Prostate Cancer - Product Description
- POC Device - Monoclonal Antibodies - Product Status
- POC Device - Monoclonal Antibodies - Product Description
- SSAT-Amantadine Assay - ELISA KIT - Product Status
- SSAT-Amantadine Assay - ELISA KIT - Product Description
- SSAT-Amantadine Assay - Raman SERS - Product Status
- SSAT-Amantadine Assay - Raman SERS - Product Description
- SSAT1 - Acetylamantadine Assay - Product Status
- SSAT1 - Acetylamantadine Assay - Product Description
- BioMark Diagnostics Inc, Key Employees
- BioMark Diagnostics Inc, Other Locations
- Glossary
- BioMark Diagnostics Inc Pipeline Products by Equipment Type
- BioMark Diagnostics Inc Pipeline Products by Development Stage
- BioMark Diagnostics Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Biocan Diagnostics Inc.
- Biomedica Diagnostics Inc
- Cytodiagnostics Inc
- Biosite Diagnostics Incorporated
